AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01213836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel XR
Description: Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
Study NCT01213836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel IR
Description: Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
Study NCT05149924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1012
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Study NCT05149924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f ®
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Study NCT00670241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol and betamethasone (LEO 80185 gel)
Description: Once daily application
Study NCT00670241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 80185 vehicle
Description: Once daily application
Study NCT00670241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacalcitol ointment
Description: Once daily application
Study NCT02251977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM1
Description: GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Study NCT02251977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 40 mg/ml, 1 ml
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 500 mg in 10 ml
Study NCT02251977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 or XELOX
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Study NCT02653872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: 500 mg in 10 ml
Study NCT03094663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8 MHz. Chiba needle
Description: 22G/ 4 inches
Study NCT03094663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 MHz. Chiba needle
Description: 22G/ 4 inches
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexamethasone
Description: 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 25cc
Description: 25 cc 0.25% bupivacaine
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 25cc
Description: 25 cc 0.25% bupivacaine
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 20cc
Description: 20cc 0.25% bupivacaine
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20cc
Description: 20cc 0.25% bupivacaine
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2 mg IV dexamethasone.
Study NCT04726501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with or without involved-field radiotherapy
Description: Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
Study NCT02251977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFOX6 or XELOX
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Study NCT02090764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozenoxacin
Study NCT02653872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Extended release tablet for oral use
Study NCT02653872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Oral solution
Study NCT02653872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: Extended release capsule
Study NCT01790880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ORLA
Description: Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
Study NCT01790880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ORLA + Writing
Description: Treatment includes writing of sentences in combination with ORLA
Study NCT00553943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 D1
Study NCT00553943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 50 mg D3
Study NCT02370563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Description: 18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
Study NCT02485236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen via nasal cannula
Description: In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
Study NCT02485236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Humidified Nasal High Flow Therapy
Description: Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
Study NCT00619645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Study NCT00619645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine
Study NCT00619645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Study NCT00619645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mycophenolate mofetil
Study NCT00619645 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00619645 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study NCT02845856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
Study NCT02845856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
Study NCT02845856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: For each procedure, 10 billion cells will be infused in 4 times
Study NCT04629118 — intervention group
Intervention type: DEVICE
Intervention: Selution SLR™ 018 Drug Eluting Balloon
Description: Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
Study NCT00005840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00005840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00005840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole abdominal radiation therapy
Study NCT01985906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple overlapping uncovered stents
Description: Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
Study NCT01985906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncovered stents
Description: The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virginia Tobacco flavored JUUL 5% ENDS
Description: Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Mint flavored JUUL 5% ENDS
Description: Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango flavored JUUL 5% ENDS
Description: Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creme Brulee flavored JUUL 5% ENDS
Description: Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VUSE Solo e-cigarette
Description: Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette White Ice Mint 4mg nicotine polacrilex gum
Description: Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
Study NCT03719391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand combustible cigarette
Description: Treatment with usual brand cigarette (10 puffs).
Study NCT03437642 — intervention group
Intervention type: BEHAVIORAL
Intervention: Short Term Psychotherapy
Description: Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
Study NCT02166021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
Study NCT02166021 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mesenchymal stem cells
Description: A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
Study NCT02963714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose
Study NCT02963714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study NCT02593747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine oral solution
Description: Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
Study NCT02593747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Claritin peach syrup)
Description: Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
Study NCT01557608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photon stimulation
Description: The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
Study NCT01557608 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment.
Study NCT04542694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets
Study NCT04542694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.
Study NCT02228109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Presbyopia
Description: Acuvue Oasys for Presbyopia contact lenses worn
Study NCT02228109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision2 for Presbyopia
Description: PureVision2 for Presbyopia contact lenses worn
Study NCT02228109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal
Description: Biofinity Multifocal contact lenses worn
Study NCT04082806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: 50 mg/kg GHB at one experimental night
Study NCT04082806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 1.5 mg/kg trazodone at one experimental night
Study NCT04082806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
Study NCT02507817 — intervention group
Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein
Study NCT02137382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon®
Description: active comparator
Study NCT02137382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon N
Description: experimental drug
Study NCT03662763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride (SPD503)
Description: dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
Study NCT03662763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT03907917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study NCT03907917 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study NCT03297086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
Study NCT01647958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophyX System with SerosaFuse fasteners
Description: Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
Study NCT01647958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Control Arm participants will take maximum standard dose of PPI during Initial Study period
Study NCT00544817 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 2 Gy/fraction, single daily fractions M-F, to 60 Gy total
Study NCT00544817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles
Study NCT00544817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
Study NCT00686244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined 3-monthly endurance and strength training
Description: Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism
Study NCT04047953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
Description: Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
Study NCT00114231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00114231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00114231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Undergo surgery
Study NCT00114231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT02612181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine for dexmedetomidine group
Description: The effect of dex and placebo for sedation on microcirculation
Study NCT02612181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine for dexmedetomidine group
Description: The effect of dex and placebo for sedation on microcirculation
Study NCT01736787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cauliflower Mushroom extract
Description: Cauliflower Mushroom extract (1g/day)
Study NCT01736787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1g/day)
Study NCT01099631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
Study NCT03370822 — intervention group
Intervention type: DEVICE
Intervention: MONICA AN24 device
Description: Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)